Using modified stem cells to target and eliminate HIV infection
Hematopoietic Stem/Progenitor Cell-Based Chimeric Antigen Receptor Gene Therapy for HIV Infection
This study is exploring a new way to treat HIV by using your own blood cells to help fight the virus, making it easier and safer than traditional treatments, with the hope of achieving long-lasting health without the virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11055233 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating HIV by modifying a patient's own hematopoietic stem/progenitor cells (HSPCs) to resist HIV infection and target infected cells for elimination. The method involves creating a chimeric antigen receptor (CAR) that directs these modified cells to specifically attack HIV. By using a more targeted gene therapy approach, the research aims to reduce the toxicities associated with traditional stem cell transplants and improve the chances of a functional cure for HIV. Patients may benefit from a less invasive treatment that could potentially lead to long-term remission from the virus.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are seeking alternative treatment options beyond traditional antiretroviral therapies.
Not a fit: Patients who are not infected with HIV or those who have contraindications for stem cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a functional cure for HIV, significantly improving the quality of life for patients living with the virus.
How similar studies have performed: Previous research has shown promise in using stem cell-based therapies for HIV, indicating potential for success with this novel approach.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Kitchen, Scott G — University of California Los Angeles
- Study coordinator: Kitchen, Scott G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.